The CMIT AI model for animal-to-human data conversion to accelerate new drug evaluation has been selected into the first batch of strategic high-value AI scenarios for central state-owned enterprises issued by SASAC. The application of AI-enabled pharmaceutical R&D has obtained national-level recognition.